Evidence map›Paper›PMID 25105290›Full record

ArticlePloS one2014

Compatibility of stabilized whole blood products with CD4 technologies and their suitability for quality assessment programs.

Tao Ding, Michèle Bergeron, Peggy Seely, Xuefen Yang, Tamsir O Diallo, Margot Plews, Paul Sandstrom, T Blake Ball, Adrienne F A Meyers

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tao DingNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Michèle BergeronNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Peggy SeelyNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Xuefen YangNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada; National Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Tamsir O DialloNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada; National Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Margot PlewsNational Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Paul SandstromNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada; National Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
T Blake BallNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya; National Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Adrienne F A MeyersNational Laboratory for HIV Immunology, Public Health Agency of Canada, Ottawa, Ontario, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya; National Laboratory for HIV Immunology, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD4 T cell enumeration is the most widely used prognostic marker for management of HIV disease. Internal quality control and external quality assessment (EQA) programs are critical to ensure reliability of clinical measurements. The utility of stabilized whole blood products (SWBP) as a test reagent for EQA programs such as Quality Assessment and Standardization for Immunological measures relevant to HIV/AIDS (QASI) program have been demonstrated previously. Since then, several new commercial SWBPs and alternative CD4 enumeration technologies have become available. Seven SWBPs were evaluated on seven different enumeration platforms to determine which product(s) are most suitable for EQA programs that support multiple analytical technologies.

methodAssessment of SWBPs was based on two criteria: (1) accuracy of CD4 T cell measurements and; (2) stability under sub optimal storage conditions.

resultsThree SWBPs (Multi-Check, StatusFlow and CD4 Count) showed accurate CD4 T-cell absolute count and percentage values across six of the enumeration platforms. All products retain stability up to 18 days at 21-23°C with the exception of Multi-Check-high on FacsCount and Multi-Check-Low and StatusFlow-Low on Pima. One of the products (CD4 Count) retained stability for three days on all platforms tested when stored at 37°C.

conclusionThis study demonstrated that the characteristics of commercially available SWBPs vary across multiple CD4 platforms. The compatibility of testing panels for EQA programs with multiple analytical platforms needs to be carefully considered, especially in large multiplatform CD4 EQA programs. The selection of a suitable cross-platform SWBP is an increasing challenge as more reagents and platforms are introduced for CD4 T-cell enumeration.

Indexed as

Biological ProductsBloodCD4-Positive T-LymphocytesCell CountHIV SeropositivityHumansImmunophenotypingQuality ControlBiological Products

Identifiers

PMID25105290
PMCPMC4126665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.